Furthermore, genetic modification of animal models, e.g., Mas-deficient mice, emerged as a valuable tool in assessing actions and interactions of MasR, yielding an increasing body of evidence that reinforces the clinical potential of MasR in the management of HT. Here, MAS1L is linked to hematocrit.